

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows, without prejudice or disclaimer. This listing of the claims replaces all prior listings.

1. (Previously Amended) A poxvirus expression vector for expressing the BFA4 protein in a cell, the vector comprising the nucleic acid sequence of SEQ ID NO.: 1, wherein administration of the vector to a mammal induces a T-cell response against the BFA4 protein.

2-3. Previously Canceled

4. (Previously Amended) The expression vector of claim 1 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

5. (Previously Amended) The expression vector of claim 4 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

6. (Previously Presented) The expression vector of claim 1 further comprising at least one additional tumor-associated antigen.

7-8. Previously Canceled

9. (Previously Amended) The expression vector of claim 6 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

10. (Previously Amended) The expression vector of claim 9 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

11. (Original) The expression vector of claim 1 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.

12-13. Previously Canceled

14. (Previously Amended) The expression vector of claim 11 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

15. (Previously Amended) The expression vector of claim 14 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

16. (Original) The expression vector of claim 6 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.

17-18. Previously Canceled

19. (Previously Amended) The expression vector of claim 16 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

20. (Previously Amended) The poxvirus of claim 19 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

21. (Previously Presented) The expression vector of claim 1, 6, 11 and 16 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.

22-23. Previously Canceled

24. (Previously Amended) The expression vector of claim 21 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

25. (Previously Amended) The poxvirus of claim 24 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

26. (Previously Amended) A composition comprising a the poxvirus expression vector of claim 1 and a pharmaceutically acceptable carrier.

27-28. Previously Canceled

29. (Previously Amended) The expression vector of claim 26 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

30. (Previously Amended) The poxvirus of claim 29 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

31-39. Cancelled

40. (Previously Presented) The expression vector of claim 6 wherein the at least one additional tumor-associated antigen has the amino acid sequence of SEQ ID NO:4.

41. (Previously Presented) The expression vector of claim 11 further comprising at least one additional nucleic acid sequence encoding a tumor-associated antigen having the amino acid sequence of SEQ ID NO:4.

42. (Previously Presented) The expression vector of claim 16 wherein the at least one additional tumor-associated antigen has the amino acid sequence of SEQ ID NO:4.

43. (Previously Presented) The expression vector of claim 21 wherein the at least one additional tumor-associated antigen has the amino acid sequence of SEQ ID NO:4.

44. (Previously Amended) A poxvirus expression vector comprising a nucleic acid sequence encoding a BFA4 protein having the amino acid sequence of SEQ ID NO:2 wherein administration of the vector to a mammal induces a T-cell response against the BFA4 protein.

45-46. Previously Canceled

47. (Previously Amended) The expression vector of claim 44 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

48. (Previously Amended) The expression vector of claim 47 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

49. (Previously Presented) The expression vector of claim 44 further comprising a nucleic acid encoding at least one additional tumor-associated antigen.

50-51. Previously Canceled

52. (Previously Amended) The expression vector of claim 49 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

53. (Previously Amended) The expression vector of claim 52 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

54. (Previously Presented) The expression vector of claim 44 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.

55-56. Previously Canceled

57. (Previously Amended) The expression vector of claim 54 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

58. (Previously Amended) The expression vector of claim 57 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).

59. (Previously Presented) The expression vector selected from the group consisting of the expression vector of claims 44, 49 and 54 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.

60-61. Previously Canceled

62. (Previously Amended) The expression vector of claim 59 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.

63. (Previously Amended) The poxvirus of claim 62 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
64. (Previously Amended) A composition comprising an expression vector of claim 44 and a pharmaceutically acceptable carrier.
65. (Previously Amended) A composition comprising an expression vector of claim 49 and a pharmaceutically acceptable carrier.
66. (Previously Amended) A composition comprising an expression vector of claim 54 and a pharmaceutically acceptable carrier.
67. (New) A poxvirus expression vector for expressing the BFA4 protein in a cell, the vector comprising the nucleic acid sequence of SEQ ID NO.: 1, wherein administration of the vector to a mammal induces a T-cell response against at least one peptide selected from the group consisting of SEQ ID NO. 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, and 110.
68. (New) The expression vector of claim 67 wherein the poxvirus is selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
69. (New) The expression vector of claim 68 wherein the poxvirus is selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).